Corticosteroid Therapy in Acute Respiratory Distress Syndrome (ARDS)

Introduction to Corticosteroid Therapy

• The American Thoracic Society suggests using corticosteroids in patients with ARDS as they probably decrease mortality and may reduce duration of mechanical ventilation, based on moderate certainty evidence 1

Efficacy of Corticosteroids

• Corticosteroids probably decrease mortality (RR 0.84; 95% CI 0.73-0.96) and may reduce duration of mechanical ventilation by approximately 4 days and length of hospital stay by approximately 8 days, according to the American Thoracic Society's 2024 clinical practice guideline 1
• A Cochrane systematic review demonstrated that low-dose hydrocortisone (<400 mg/day) for 3 or more days significantly reduced the risk of death at 28 days compared to placebo, as reported by the Intensive Care Medicine journal 2

Timing of Corticosteroid Therapy

• Early initiation of corticosteroids (<72 hours) is associated with better response to lower doses, faster disease resolution, shorter time to unassisted breathing, and shorter ICU stay 2
• Starting corticosteroids more than 14 days after ARDS onset may increase mortality, as stated by the American Thoracic Society 1
• Initiation of corticosteroids more than 14 days after ARDS onset may be associated with harm 1

Dosing and Administration

• The ideal steroid treatment for patients with both septic shock and ARDS is intravenous hydrocortisone at a dose of 200-300 mg/day for at least 3 days, with methylprednisolone 1 mg/kg/day being an appropriate alternative specifically for the ARDS component, as recommended by the Society of Critical Care Medicine and European Society of Intensive Care Medicine 2
• The following dosing protocols are recommended:

• An alternative to methylprednisolone is prednisolone 30 mg/day orally for 7-14 days, as suggested by the British Thoracic Society 3
• Dexamethasone dosing regimen is 20 mg IV daily for days 1-5, followed by 10 mg IV daily for days 6-10, as conditionally recommended by the American Thoracic Society for ARDS patients 1
• Hydrocortisone treatment should be continued until shock reversal (vasopressors no longer required) but for at least 3 days, according to the Society of Critical Care Medicine 2
• The treatment duration should be at least until vasopressors are no longer required, as suggested by the European Society of Intensive Care Medicine 2, 4

Monitoring and Precautions

• Corticosteroids probably increase the risk of hyperglycemia (RR 1.11; 95% CI 1.01-1.23) and may increase the risk of gastrointestinal bleeding (RR 1.20; 95% CI 0.43-3.34), according to the American Thoracic Society's guidelines 1
• Regular blood glucose monitoring is necessary when administering corticosteroids for ARDS, as recommended by the American Thoracic Society 1
• Blood glucose should be monitored closely due to the increased risk of hyperglycemia, as suggested by the Society of Critical Care Medicine 2
• Patients on hydrocortisone therapy should be watched for hypernatremia, especially with prolonged treatment, according to the European Society of Intensive Care Medicine 2
• Monitor patients on corticosteroids for hyperglycemia, potential gastrointestinal bleeding, and new infections, and consider prophylactic antibiotics to prevent opportunistic infections 2, 5
• Exercise caution in viral pneumonia (especially influenza-associated ARDS) as corticosteroids may increase mortality, although the specific citation for this fact was ignored, the general principle is supported by 2
• Patients with viral pneumonia, immunocompromised patients, patients with metabolic syndrome, and patients in regions with endemic tuberculosis or parasitic diseases require exercise caution when administering corticosteroids for ARDS 1

Special Considerations

• High-dose short-course steroids are less effective than lower doses for longer duration, as suggested by the Society of Critical Care Medicine 2
• Abrupt cessation of corticosteroids should be avoided, and tapering should be considered to prevent rebound effects, according to the European Society of Intensive Care Medicine 2, 4
• Continuous infusion of hydrocortisone is preferred over bolus injections to avoid glucose spikes, as recommended by the Critical Care Medicine society 4